CA2381302A1 - Medicament pour traiter des fractures - Google Patents

Medicament pour traiter des fractures Download PDF

Info

Publication number
CA2381302A1
CA2381302A1 CA002381302A CA2381302A CA2381302A1 CA 2381302 A1 CA2381302 A1 CA 2381302A1 CA 002381302 A CA002381302 A CA 002381302A CA 2381302 A CA2381302 A CA 2381302A CA 2381302 A1 CA2381302 A1 CA 2381302A1
Authority
CA
Canada
Prior art keywords
bone
drug
bisphosphonate
group
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381302A
Other languages
English (en)
Inventor
David G. Little
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381302A1 publication Critical patent/CA2381302A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un médicament choisi dans un groupe constitué de bisphosphonates, qui est destiné à favoriser la croissance osseuse et à traiter des fractures.
CA002381302A 1999-08-19 2000-08-17 Medicament pour traiter des fractures Abandoned CA2381302A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPQ2325 1999-08-19
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (fr) 1999-08-19 2000-08-17 Medicament pour traiter des fractures

Publications (1)

Publication Number Publication Date
CA2381302A1 true CA2381302A1 (fr) 2001-03-01

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381302A Abandoned CA2381302A1 (fr) 1999-08-19 2000-08-17 Medicament pour traiter des fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (fr)
JP (1) JP2003507426A (fr)
KR (1) KR20020027562A (fr)
CN (1) CN100345548C (fr)
AU (1) AUPQ232599A0 (fr)
BR (1) BR0013416A (fr)
CA (1) CA2381302A1 (fr)
HK (1) HK1048441B (fr)
HU (1) HUP0202396A3 (fr)
IL (1) IL148166A0 (fr)
NO (1) NO20020784L (fr)
NZ (1) NZ517538A (fr)
PL (1) PL353485A1 (fr)
SK (1) SK2382002A3 (fr)
WO (1) WO2001013922A1 (fr)
ZA (1) ZA200202160B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365769B1 (fr) * 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) Medicament destine au traitement de l'osteonecrose et a la gestion de patients etant predisposes a l'osteonecrose
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
CA2539359A1 (fr) * 2003-09-19 2005-03-31 Pfizer Products Inc. Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
ES2379485T3 (es) * 2005-10-27 2012-04-26 Thommen Medical Ag Implante dental y procedimiento para su fabricación
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
EP0600834A1 (fr) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Utilisation de dérivés de l'acide méthanediphosphonique pour la fabrication d'un médicament pour le traitement de fractures
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
WO1994014455A1 (fr) * 1992-12-23 1994-07-07 Merck & Co., Inc. Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
WO1996039150A1 (fr) * 1995-06-06 1996-12-12 Merck & Co., Inc. Traitement par bisphosphonates de la deperdition osseuse associee a l'arthrite rhumatoide
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
KR20020027562A (ko) 2002-04-13
ZA200202160B (en) 2003-08-27
NZ517538A (en) 2003-07-25
IL148166A0 (en) 2002-09-12
JP2003507426A (ja) 2003-02-25
NO20020784D0 (no) 2002-02-18
WO2001013922A1 (fr) 2001-03-01
PL353485A1 (en) 2003-11-17
BR0013416A (pt) 2002-04-30
HUP0202396A3 (en) 2005-02-28
CN1370071A (zh) 2002-09-18
CN100345548C (zh) 2007-10-31
HK1048441A1 (en) 2003-04-04
SK2382002A3 (en) 2002-09-10
HUP0202396A2 (hu) 2002-11-28
HK1048441B (zh) 2008-02-22
AUPQ232599A0 (en) 1999-09-09
EP1214079A4 (fr) 2004-03-24
NO20020784L (no) 2002-02-18
EP1214079A1 (fr) 2002-06-19

Similar Documents

Publication Publication Date Title
Yıldız et al. Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model
WO2002098307A1 (fr) Dispositif permettant l'apport d'un medicament a un os fracture
Little et al. Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits
US20040157798A1 (en) Drug for use in bone grafting
JPH09512268A (ja) 整形外科的人工器官移植後の骨吸収を阻害するためのビスホスホネートの使用
JPH08510996A (ja) 骨の手術へのビスホスホネートの使用
Pampu et al. Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis
NO310057B1 (no) Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering
CA2381302A1 (fr) Medicament pour traiter des fractures
Küçük et al. Comparison of local and systemic alendronate on distraction osteogenesis
Little et al. Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis
AU5973496A (en) Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP2953632A1 (fr) Carbonate de calcium amorphe pour croissance osseuse accélérée
Tarvainen et al. Effect of clodronate on fracture healing in denervated rats
Harding et al. A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients
AU781068B2 (en) Drug for treating fractures
CA2353528C (fr) Utilisation d'ibandronate pour favoriser l'osseointegration des endoprotheses
Kurth et al. Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat
Goodship et al. Prevention of strain‐related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate
Alshahrani et al. Ranitidine impairs bone healing and implant osseointegration in rats' tibiae
Kakar et al. Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals
Saghieh et al. The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study
Heidari et al. Effect of risedronate on bone resorption during the consolidation phase of distraction osteogenesis: a rabbit model
RU2816809C1 (ru) Способ прагматизации репаративного остеогенеза трубчатых костей животных
Min et al. Nonsurgical treatment strategies after osteoporotic hip fractures

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued